Makita, S., Maruyama, D., & Tobinai, K. (2020). Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma. Onco Targets Ther.
Chicago-stil citatMakita, Shinichi, Dai Maruyama, och Kensei Tobinai. "Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma." Onco Targets Ther 2020.
MLA-referensMakita, Shinichi, Dai Maruyama, och Kensei Tobinai. "Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma." Onco Targets Ther 2020.
Varning: dessa hänvisningar är inte alltid fullständigt riktiga.